ADL Amdl,

FY09 revenue and net income estimated to increase at least 100% from FY08 TUSTIN, Calif., Nov. 18 /PRNewswire-FirstCall/ -- AMDL, Inc. (AMEX:ADL), a vertically integrated pharmaceutical company with operations in China and the US, announced today preliminary fiscal 2009 financial guidance. The Company is forecasting robust growth in 2009, anticipating gross revenues for the year to range between $64 and $72 million with net income between $8 and $12 million before foreign currency translation. AMDL's growth will be supported by: -- R&D and product development for products with higher gross-profit- margins; -- Refined sales, marketing and branding strategies to promote the sales of products with higher gross-profit-margins while increasing the associated market share; -- Increasing its core sales and distribution teams which will focus on selling in major cities in China supporting 1 million or more citizens, and selling select products in other international markets; -- Leveraging our US and China-based production plants to ensure necessary quantities of both new and existing products are available to meet customer demand; and, -- Commercializing other key products including AMDL's DR-70(R) ELISA in vitro diagnostic cancer test and new product formulations for its best-selling Goodnak(R) anti-aging product line. This guidance does not include potential future acquisitions or sales from its Combination Immunogene Therapy technology and management will continue to evaluate its business outlook as necessary and communicate any changes on a quarterly basis or when appropriate. AMDL will discuss its business outlook during its regular quarterly conference call which is scheduled for today, Tuesday November 18, 2008 at 6:30 a.m. Pacific Time (9:30 a.m. Eastern Time). Listeners may access the call by dialing 1-877-360-1705 or 1-706-902-3245 for international callers, access code: 12310; conference ID 74287692. To listen to the conference call after the live presentation, or to view the financial or other statistical information required by Securities and Exchange Commission (SEC) Regulation G, please visit the Investors section of the AMDL website at http://www.amdl.com/. The conference call will be recorded and available for listening until 5:00 p.m. Pacific Time, Wednesday, November 19, 2008. About AMDL: Headquartered in Tustin, CA with operations in Shenzhen, Jiangxi, and Jilin, China, AMDL, Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a vertically integrated bio-pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The company employs over 490 people in the U.S. and China. Forward Looking Statements: Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward- looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to AMDL Inc., except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties related to the Company's access to additional capital, competition and dependence on key management. AMDL Contact: Kristine Szarkowitz Director-Investor Relations (Tel :) 206.310.5323 DATASOURCE: AMDL, Inc. CONTACT: Kristine Szarkowitz, Director-Investor Relations of AMDL, +1-206-310-5323, Web site: http://www.amdl.com/

Copyright